CompanyPTC Therapeutics, Inc.
United States of America
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders.
Private/Public:
public
Phone:908 222 7000
Fax:908 222 7231
Email:[email protected]
Website:https://www.ptcbio.com/
Address:100 Corporate Court, South Plainfield, NJ 07080-2449, United States of America
1998
Since
1
Country
1
Top Service Category
4
Sub-Service Categories
Product Groups
For Services/Products
Diagnostics
Diagnostic Testing Services - Genomic/Non-genomic
United States of America
- (03.May.2022) PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
- (29.Apr.2022) New Three-Year Data for Genentech's Evrysdi (Risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
- (14.Apr.2022) PTC Therapeutics Provides Update on EMA Regulatory Review Timeline for Its AADC Deficiency Gene Therapy Program
- (08.Apr.2022) PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- (30.Mar.2022) PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients With Huntington's Disease
- (16.Mar.2022) New Data for Genentech's Evrysdi (Risdiplam) Demonstrate Long-Term Efficacy and Safety in a Broad Population of People With Spinal Muscular Atrophy (SMA)
- (22.Feb.2022) PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
- (03.Feb.2022) Roche Canada and the Pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for EVRYSDIⓇ (Risdiplam) for the Treatment of Adults and Children With Spinal Muscular Atrophy (SMA)
- (25.Jan.2022) FDA Grants Evrysdi Priority Review Based on Results From Treating Pre-Symptomatic Infants With Spinal Muscular Atrophy
- (13.Jan.2022) PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- (10.Jan.2022) PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference
- (04.Jan.2022) Waylivra Receives Innovative Drug Category Pricing to Treat Familial Chylomicronemia Syndrome in Brazil
- (20.Dec.2021) Oral Splicing Modifiers That Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform
- (08.Dec.2021) Gene Therapy PTC-AADC Provides Benefits for 5 Years in Children
- (06.Dec.2021) Evrysdi Distinguished by Two Prestigious Awards for Outstanding Innovation in Drug Discovery
- (02.Dec.2021) PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- (22.Nov.2021) UK's NICE Recommends Roche's Evrysdi
- (28.Oct.2021) PTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results
- (25.Oct.2021) PTC Announces Expansion of Translarna Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil
- (14.Oct.2021) PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility
- (11.Oct.2021) Tegsedi Receives Innovative Drug Category Pricing in Brazil
- (06.Oct.2021) Parent Project Muscular Dystrophy's Ground-Breaking Effort: Completion of a Successful Pilot in Newborn Screening for Duchenne Muscular Dystrophy
- (29.Sep.2021) PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- (29.Sep.2021) Results Show Long-Lasting and Holistic Improvements in Children With AADC Deficiency Treated With PTC-AADC Gene Therapy
- (24.Sep.2021) Roche Presents New Data at World Muscle Society (WMS) 2021 Highlighting New Advances for People Living with Rare Neuromuscular Disorders
- (20.Sep.2021) STRIDE Data Show Translarna Delays Loss of Ambulation by More Than Five Years in Boys With Nonsense Mutation Duchenne Muscular Dystrophy
- (07.Sep.2021) PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community
- (30.Aug.2021) Evrysdi (Risdiplam) Receives CADTH Reimbursement Recommendation for Some Patients With Spinal Muscular Atrophy
- (23.Aug.2021) Targeting the Putamen With Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children With AADC Deficiency
- (23.Aug.2021) PTC Therapeutics Announces Waylivra Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome
- (20.Aug.2021) PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- (12.Aug.2021) Chugai Launches Evrysdi Dry Syrup 60 Mg for the Treatment of Spinal Muscular Atrophy
- (29.Jul.2021) Data for Roche's Evrysdi (Risdiplam) Published in New England Journal of Medicine Shows Significant Improvement in Survival and Motor Milestones in Babies with Type 1 Spinal Muscular Atrophy (SMA)
- (29.Jul.2021) PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results
- (28.Jul.2021) Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated With Evrysdi
- (24.Jun.2021) Results Add to Body of Evidence Confirming EMFLAZA's Benefit Over Prednisone
- (23.Jun.2021) Evrysdi Approved in Japan for the Treatment of Spinal Muscular Atrophy
- (15.Jun.2021) PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- (11.Jun.2021) New Genentech Data for Evrysdi (Risdiplam) Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People With Spinal Muscular Atrophy (SMA)
- (11.Jun.2021) Pre-Symptomatic Infants With Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment With Evrysdi in RAINBOWFISH